Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Pentazocine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 10/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 4/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | EBP | Q15125 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentazocine SCHEMBL2493 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL30132413 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| Rel-Pentazocine SCHEMBL135685 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL16220021 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL16144643 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL18672553 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL4376337 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL680675 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL22865258 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| Pentazocine SCHEMBL29611805 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 36959 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122087518-A | Method for classifying anesthetic drugs by using neural network | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075497-A | Use of NLRP3 agonist for tumor treatment | — | 2026-05-26 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-4714444-A1 | PREPARATION FOR AND USE OF CANNABIDIOL DERIVATIVE DRUGS | Changchun Institute Of Applied Chemistry Chinese Academy Of Sciences (CN) | 2026-03-25 | — | — | EP | claimed |
| US-4434168-A | Narcotic antagonists in the therapy of shock | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1984-02-28 | — | — | US | claimed |
| WO-1984000488-A1 | IMPROVED ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CAFFEINE AND METHODS OF USING SAME | RICHARDSON VICKS INC (US) | 1984-02-16 | — | — | WO | claimed |
| EP-0077393-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | The University of Kentucky Research Foundation (US) | 1983-04-27 | — | — | EP | claimed |
| WO-1982003768-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | UNIV KENTUCKY (US) | 1982-11-11 | — | — | WO | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |
| US-4267182-A | Narcotic antagonists in the therapy of shock | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1981-05-12 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
| US-4168308-A | Composition for enhancing the administration of pharmacologically active agents | APOTEKSVARUCENTRALEN VITRUM AB (SE) | 1979-09-18 | — | — | US | claimed |
| US-4022878-A | NATIVE HOMOLOGOUS HAPTEN OR ANTIGEN | BIOLOGICAL DEVELOPMENTS, INC. (US) | 1977-05-10 | — | — | US | claimed |